Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Bisphosphonate
•
Primary Care
Do you use bisphosphonates in combination with SERMs in female patients with progressive decline in bone density despite being on a SERM for post-menopausal symptoms other than osteoporosis?
Related Questions
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
Do you start bisphosphonates after tapering off menopausal hormone therapy to prevent the rapid decline of bone mineral density?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
How do you approach management of osteoporosis in patients post lung transplant?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy? If you workup all patients, what labs do you find most helpful to start with?
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
What is your approach to management of patients with recurrent nephrolithiasis and osteoporosis who are receiving teriparatide?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
